Viralytics sees 'significant validation' Share via Email Share...

Viralytics sees 'significant validation'

• Share via Email
• Share on Google Plus
• Post on facebook wall
• Share on twitter
• Post to Linkedin
• Share on Reddit

NaN of
http://www.copyright link/content/dam/images/1/0/f/a/g/6/image.related.afrArticleLead.620x350.gkv40v.png/1447120666060.jpg
The treatment landscape for many of the more common cancers continues to expand.
http://www.copyright link/content/dam/images/1/3/s/g/4/c/image.imgtype.afrAuthorAvatar.120x120.png/1425255670071.png

• Share on twitter
• Share on Google Plus

by Elise Shaw
Bell Potter maintains a "speculative buy" on Viralytics that is researching potential cancer treatments.
"The treatment landscape for many of the more common cancers continues to expand thanks to the success of the combination of checkpoint inhibitors drugs such as Merck's anti – PD1 therapy Keytrudawith new drugs such as CAVATAK.
"Friday's announcement that Merck and Viralytics are to collaborate in a combination study of CAVATAK and Keytruda while not surprising, is a significant validation of Viralytics' clinical trial program and its strategy to initiate the STORM study."
Bell Potter has a price target of 96¢ on the stock.


Read more: http://www.copyright link/markets/e...cant-validation-20151110-gkv40v#ixzz3rAm1JeCU
Follow us: @FinancialReview on Twitter | financialreview on Facebook